Arcus Biosciences, Inc.
RCUS · NYSE
Bulios Fair Price
$33.67
39.8% upside
Current Price
$24.08
According to Bulios Fair Price, RCUS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Arcus Biosciences, Inc. (RCUS) is an American biotechnology company focused on researching and developing new drugs for the treatment of oncology and inflammatory diseases. The company specializes in discovering innovative therapeutic drugs based on immunotherapy and cell growth pathway inhibition. Its research and development efforts are aimed at boosting the immune system's ability to fight against cancer cells and inflammatory processes. Arcus Biosciences collaborates with pharmaceutical companies and academic institutions in the discovery and development of new drugs and therapies. The company aims to bring innovative treatment options to patients facing challenging and difficult-to-treat diseases. Arcus Biosciences, Inc. is recognized for its research potential and influential position in the field of immuno-oncology. Arcus Biosciences, Inc. (RCUS) shares may represent an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with an innovative portfolio of research in oncology and immunotherapy.
Sector
Healthcare
Industry
Biotechnology
CEO
Terry J. Rosen
Employees
601
Headquarters
Hayward
Upcoming events
Earnings
Upcoming earnings report